Boehringer Ingelheim's Commitment to Cardio-Kidney-Metabolic Research: A Comprehensive Approach to Patient Care
Boehringer Ingelheim, a renowned pharmaceutical company with a rich history in human and animal health, is at the forefront of cardio-kidney-metabolic research, showcasing its dedication to improving patient outcomes through innovative therapies. At the American Heart Association Scientific Sessions 2025, Neerja Balachander, MBBS, PhD, emphasized the company's pioneering role in bridging the gap between cardiology, nephrology, and metabolic medicine.
The Interconnected Nature of Cardio-Kidney-Metabolic Diseases
The key to understanding the interconnected nature of heart and kidney health lies in the intricate network of blood vessels within the kidney. Balachander explains that the kidney's tiny filters, consisting of a million filters on each side, are made of a series of blood vessels, almost down to the level of a single capillary. When these blood vessels leak or encounter problems, such as inflammation or stretching due to diabetes, they start leaking protein, particularly albumin, into the urine. This is a critical sign of endothelial dysfunction, a condition that can have far-reaching consequences.
Early Intervention and Long-Term Risk Reduction
The impact of this interconnectedness on cardiovascular events is profound. Balachander highlights that kidney disease significantly increases the risk of heart attacks and heart-related complications, with patients six times more likely to die of a heart attack than to require dialysis. Alarmingly, nine out of ten patients with chronic kidney disease remain unaware of their condition. However, a simple solution exists: measuring the albumin-to-creatinine ratio in urine. This inexpensive test can identify patients at risk and should be considered a crucial risk enhancer, alongside factors like blood pressure, diabetes status, cholesterol levels, and smoking history.
Addressing the Challenge: Education and Implementation
The challenge lies in implementing these risk assessment practices. Balachander emphasizes the need for education and awareness, drawing a parallel to cardiology practices where assessing diabetic status and blood pressure is standard. However, the distance from urine testing and the overwhelming workload of primary care physicians, spending only eight minutes per patient, contribute to the oversight of albuminuria as a major risk factor in cardiac disease.
Boehringer Ingelheim's Vision and Efforts
Boehringer Ingelheim's commitment to cardio-kidney-metabolic research aligns seamlessly with its broader vision of improving patient outcomes. Balachander highlights the company's pioneering work in studying empagliflozin for cardiovascular risk reduction and chronic kidney disease, showcasing how treatments can address multiple organ systems within the cardio-kidney-metabolic continuum. With agents like survodutide and vicasatostat, the company continues to invest in cardiovascular risk reduction, firmly dedicated to advancing therapies across the cardio-kidney-metabolic space.
The Way Forward: Collaboration and Actionable Solutions
To address the challenges effectively, collaboration is key. The National Kidney Foundation (NKF), American Diabetes Association (ADA), and American Heart Association (AHA) are partnering with organizations like Boehringer Ingelheim to develop concise, actionable lists of risk factors that clinicians and physicians can use in daily practice. This collaborative effort aims to simplify the implementation process and improve patient care.
